6074 Bevacizumab (bev) combined with chemotherapy as 2nd-line treatment for metastatic colorectal cancer (mCRC): results from the phase II BEVACOLOR study

Article de revue

Avec comité de lecture

J. Bennouna, F. Husseini, J.P. Delord, C. Borg, V. Trillet-Lenoir, R. Faroux, E. Francois, M. Ychou, B. Chaaban et J.Y. Douillard

European journal of cancer supplements, Vol.7(2), pp.344-344

2009

Indicateurs

1 Consultations de la notice

Titre: 6074 Bevacizumab (bev) combined with chemotherapy as 2nd-line treatment for metastatic colorectal cancer (mCRC): results from the phase II BEVACOLOR study
Créateurs - sans rôle: J. Bennouna
F. Husseini
J.P. Delord
C. Borg
V. Trillet-Lenoir
R. Faroux
E. Francois
M. Ychou
B. Chaaban
J.Y. Douillard
Détails de publication: European journal of cancer supplements, Vol.7(2), pp.344-344
Identifiants: 99140178709311
Unité académique: Institut de Recherche en Cancérologie de Montpellier - IRCM
Langue: English
Type de ressource: Journal article